Trademark: 79266778
Status Date
Tuesday, February 23, 2021
Registration Number
6274672
Registration Date
Tuesday, February 23, 2021
Filing Date
Wednesday, November 28, 2018
Published for Opposition
Tuesday, December 8, 2020
5 Pharmaceutical comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases and other pathologies, treatable or improvable through use of antibodies that bind to, activate or block the target antigens; medicines comprising monoclonal antibodies and/or derivatives thereof for human medicine for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; medicines comprising monoclonal antibodies and/or derivatives thereof for veterinary use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical pharmaceutical products comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; diagnostic preparations for medical use comprising monoclonal antibodies and/or derivatives thereof; chemical preparations comprising monoclonal antibodies and/or derivatives thereof for pharmaceutical use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical preparations for veterinary use comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases
1 Chemicals, biochemicals, biological preparations and enzymes from biotechnological processes for use in industry and science; chemicals, biochemicals, biological preparations and enzymes, antibodies and antibody fragments, from biotechnological processes, for development and manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof; biological products comprising monoclonal antibodies and/or derivatives thereof, namely, antibodies and antibody fragments for use in laboratories, diagnosis and analysis for scientific and research purposes; chemical and biochemical additives, carriers and substances for manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof
44 Medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the fields of immuno-oncology, oncology and immunology; provision of medical information; Medical service featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the nature of preparation and administration of medicines in the field of immuno-oncology, oncology and immunology; advice in connection with dietetics and nutrition; advice with respect to health and provision of health information in the fields of immuno-oncology, oncology and immunology; veterinary services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; hygienic and beauty care for humans and animals; provision of information on diagnostic, prophylactic and therapeutic properties of drugs in the fields of immuno-oncology, oncology and immunology
42 Research and development services in the field of pharmaceutical preparations, biotechnology, antibodies and antibody fragments, proteins, micro-organisms and cells for therapeutic purposes; research services with respect to pharmaceutical preparations, biotechnology, antibody therapy and gene therapy; scientific and technological services of a chemical and molecular biological laboratory; research, product development and quality control services in the field of pharmacy, medical diagnostics and medical therapy; research services in the field of chemistry and biology; industrial analysis and research services in the field of pharmacy, medical diagnosis, and medical therapy; research and development services for antibody products for therapeutic purposes; conducting and preparing chemical, biochemical and biotechnological analysis and research
Dec 31, 2023
New Representative At Ib Received
Aug 27, 2021
New Representative At Ib Received
Jun 13, 2021
Final Decision Transaction Processed By Ib
Jun 6, 2021
Change Of Owner Received From Ib
May 26, 2021
Final Disposition Notice Sent To Ib
May 26, 2021
Final Disposition Processed
May 23, 2021
Final Disposition Notice Created, To Be Sent To Ib
Mar 1, 2021
Correction From The Ib Examined, No Action Is Needed
Feb 28, 2021
Correction Transaction Received From Ib
Feb 23, 2021
Registered-Principal Register
Dec 8, 2020
Official Gazette Publication Confirmation E-Mailed
Dec 8, 2020
Published For Opposition
Dec 6, 2020
Notification Processed By Ib
Nov 18, 2020
Notification Of Possible Opposition Sent To Ib
Nov 18, 2020
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Nov 18, 2020
Notification Of Notice Of Publication E-Mailed
Oct 30, 2020
Approved For Pub - Principal Register
Oct 13, 2020
Teas/Email Correspondence Entered
Oct 13, 2020
Correspondence Received In Law Office
Oct 13, 2020
Assigned To Lie
Sep 1, 2020
Teas Response To Office Action Received
Mar 6, 2020
Notification Of Non-Final Action E-Mailed
Mar 6, 2020
Non-Final Action E-Mailed
Mar 6, 2020
Non-Final Action Written
Feb 14, 2020
Teas/Email Correspondence Entered
Feb 13, 2020
Correspondence Received In Law Office
Feb 13, 2020
Teas Response To Office Action Received
Feb 14, 2020
Correction From The Ib Examined, No Action Is Needed
Feb 7, 2020
Correction Transaction Received From Ib
Nov 14, 2019
Change Of Name/Address Rec'd From Ib
Oct 19, 2019
Refusal Processed By Ib
Sep 28, 2019
Non-Final Action Mailed - Refusal Sent To Ib
Sep 28, 2019
Refusal Processed By Mpu
Sep 18, 2019
Non-Final Action (Ib Refusal) Prepared For Review
Sep 17, 2019
Non-Final Action Written
Sep 17, 2019
Application Filing Receipt Mailed
Sep 13, 2019
Assigned To Examiner
Sep 13, 2019
New Application Office Supplied Data Entered
Sep 5, 2019
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
